Reaction

Adenocarcinoma Of Colon reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,850 reports · 51 co-occurring drugs

As of the last recalculation, Adenocarcinoma Of Colon appears in 1,850 FAERS reports alongside 51 co-occurring drug terms. The strongest observed disproportionality signal is PANITUMUMAB (PRR 81.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Panitumumab	107	81.5	82.1
Regorafenib	29	28.5	28.6
Oxaliplatin	158	26.1	26.2
Fluorouracil Cream, 0.5%	154	24.7	24.7
Fluorouracil	155	24.5	24.6
Melphalan	33	16.6	16.6
Baricitinib	14	16.5	16.5
Melphalan Hydrochloride	33	15.1	15.1
Ganciclovir	12	13.3	13.3
Ganciclovir Sodium	12	12.8	12.8
Bevacizumab	130	12.6	12.6
Bendamustine Hcl	17	12.4	12.5
Dalteparin Sodium	11	11.8	11.8
Cetuximab	31	11.3	11.3
Leucovorin Calcium	19	11.3	11.3
Polyethylene Glycol	10	10.4	10.5
Micafungin Sodium	7	9.3	9.3
Capecitabine	73	9.3	9.3
Irinotecan Hydrochloride	10	8.8	8.8
Fludarabine Phosphate	29	8.4	8.4
Cladribine	7	8.2	8.2
Nebivolol	11	7.8	7.8
Basiliximab	8	7.7	7.7
Ustekinumab	64	7.3	7.3
Bortezomib	55	7.1	7.1
Amiodarone Hydrochloride	7	7.1	7.1
Febuxostat Tablets 40 Mg	6	6.7	6.7
Febuxostat Tablets 80 Mg	6	6.7	6.7
Bendamustine Hydrochloride	7	6.6	6.6
Vemurafenib	7	6.6	6.6
Aflibercept	18	6.5	6.5
Imatinib	10	6.4	6.4
Trifluridine And Tipiracil	6	6.3	6.3
Vedolizumab	47	6.3	6.3
Daratumumab	22	6.3	6.3
Lenalidomide	203	5.9	6.0
Iron Sucrose	5	5.9	5.9
Thalidomide	18	5.6	5.6
Dexamethasone 1.5 Mg	136	5.6	5.6
Tofacitinib Citrate	6	5.2	5.2
Entecavir	5	4.8	4.8
Obinutuzumab	7	4.8	4.8
Ixazomib	11	4.3	4.3
Ivacaftor	3	4.3	4.3
Trametinib	8	3.7	3.7
Natalizumab	58	3.7	3.7
Dabigatran Etexilate	25	3.7	3.7
Lapatinib	5	3.6	3.6
Ofatumumab	10	3.4	3.4
Abiraterone	4	3.3	3.3
Pomalidomide	19	2.1	2.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.